- Home
- SFL vs EVO Comparison
SFL vs EVO Comparison
Compare SFL & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- EVO
- Stock Information
- Founded
- SFL 2003
- EVO 1993
- Country
- SFL Bermuda
- EVO Germany
- Employees
- SFL N/A
- EVO N/A
- Industry
- SFL Marine Transportation
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- EVO Health Care
- Exchange
- SFL Nasdaq
- EVO Nasdaq
- Market Cap
- SFL 1.1B
- EVO 1.5B
- IPO Year
- SFL N/A
- EVO 2021
- Fundamental
- Price
- SFL $8.94
- EVO $4.20
- Analyst Decision
- SFL Strong Buy
- EVO Buy
- Analyst Count
- SFL 1
- EVO 2
- Target Price
- SFL $13.00
- EVO $5.90
- AVG Volume (30 Days)
- SFL 1.2M
- EVO 114.3K
- Earning Date
- SFL 08-13-2025
- EVO 08-13-2025
- Dividend Yield
- SFL 12.12%
- EVO N/A
- EPS Growth
- SFL N/A
- EVO N/A
- EPS
- SFL 0.41
- EVO N/A
- Revenue
- SFL $852,590,000.00
- EVO $851,944,444.00
- Revenue This Year
- SFL N/A
- EVO $10.08
- Revenue Next Year
- SFL $3.20
- EVO $10.99
- P/E Ratio
- SFL $22.38
- EVO N/A
- Revenue Growth
- SFL 6.58
- EVO 1.50
- 52 Week Low
- SFL $6.78
- EVO $2.84
- 52 Week High
- SFL $14.05
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- SFL 57.51
- EVO 52.95
- Support Level
- SFL $8.79
- EVO $4.04
- Resistance Level
- SFL $9.24
- EVO $4.26
- Average True Range (ATR)
- SFL 0.20
- EVO 0.11
- MACD
- SFL 0.04
- EVO -0.01
- Stochastic Oscillator
- SFL 75.24
- EVO 51.61
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.